Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06616025Phase 3Recruiting

This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.

Role: lead

NCT05565846Unknown

NTX-001 to Repair Peripheral Nerve Transection(s)

Role: lead

NCT04572906Phase 2Completed

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

Role: lead

NCT05293522Phase 2Terminated

A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Role: lead

NCT03236064Phase 1Unknown

Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury

Role: collaborator

All 5 trials loaded